Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis

Bone Marrow Transplantation

Volumn 40, Issue 6, 2007, Pages 549-555

  Oyama, Y ^a   Barr, W G ^a   Statkute, L ^a   Corbridge, T ^a   Gonda, E A ^a   Jovanovic, B ^a   Testori, A ^a   Burt, R K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AUTOANTIBODY; CEFEPIME; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIFLORASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; HYOSCYAMINE; INFLIXIMAB; LEFLUNOMIDE; LEVOFLOXACIN; LISINOPRIL; MESNA; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENTAMIDINE; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VALACICLOVIR;

ACUTE KIDNEY FAILURE; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE PAIN; CLINICAL TRIAL; COLITIS; CRYOPRESERVATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FEVER; FOLLOW UP; HEART EJECTION FRACTION; HEART VENTRICLE OVERLOAD; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY FUNCTION; LEUKAPHERESIS; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG FUNCTION TEST; LUNG INFILTRATE; MALE; MELENA; NAUSEA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SERUM SICKNESS; SIDE EFFECT; STEM CELL MOBILIZATION; SYSTEMIC SCLEROSIS; VOMITING;

ADULT; BLOOD SEDIMENTATION; CHILD; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PLATELET TRANSFUSION; PROGNOSIS; PULMONARY WEDGE PRESSURE; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SKIN; STROKE VOLUME; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 34548536587     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705782     Document Type: Article

References (40)

1. Adams KM, Nelson JL. Microchimerism: An investigative frontier in autoimmunity and transplantation. JAMA 2004; 291: 1127-1131.
2. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004; 364: 603-610.
3. Abraham DJ, Varga J. Scleroderma: From cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587-595.
4. Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
5. Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: Early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-739.
6. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R et al. High-dose immunosuppressive therapy for severe systemic sclerosis: Initial outcomes. Blood 2002; 100: 1602-1610.
7. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR registry. Ann Rheum Dis 2004; 63: 974-981.
8. McSweeney P, Furst D, Crofford L, McDonagh K, Sullivan K. High-dose immunosuppressive therapy (HDIT) for severe systemic sclerosis (SSc): long-term survivors show continued improvement of function and skin with stability in the lungs. Blood 2004; 104: 46a.
9. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen CS, Godwin JD et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study. Blood 2007 (E-pub ahead of print).
10. Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: The evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum 2006; 54: 3750-3760.
11. Statkute L, Verda L, Oyama Y, Traynor A, Villa M, Shook T et al. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 317-329.
12. Burt RK, Patel D, Thomas J, Yeager A, Traynor A, Heipe F et al. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: Concerns over the use of total-body irradiation in systemic sclerosis. Bone Marrow Transplant 2004; 34: 745-751.
13. Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
14. Voltarelli JC, Couri CEB, Oliveira MC, Moraes DA, Pieroni F, Countinho M et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes. JAMA 2007; 297: 1568-1576.
15. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 1892-1896.
16. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Scleroderma lung study research group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
17. Oyama Y, Cohen B, Traynor A, Brush M, Rodriguez J, Burt RK. Engraftment syndrome: A common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant 2002; 29: 81-85.
18. Marie I, Levesque H, Ducrotte P, Denis P, Hellot MF, Benichou J et al. Gastric involvement in systemic sclerosis: A prospective study. Am J Gastroenterol 2001; 96: 77-83.
19. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL et al. Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-2989.
20. Furst DE, Clements PJ, Hillis S, Lachenbruch PA, Miller BL, Sterz MG et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 1989; 32: 584-593.
21. van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-372.
22. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358.
23. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-212.
24. Casas JA, Saway PA, Villarreal I, Nolte C, Menajovsky BL, Escudero EE et al. 5-fluorouracil in the treatment of scleroderma: A randomized, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990; 49: 926-928.
25. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993; 36: 75-83.
26. Steen VD, Medsger Jr TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): A retrospective analysis. Ann Intern Med 1982; 97: 652-659.
27. Stratton RJ, Wilson H, Black CM. Pilot study of antithymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001; 40: 84-88.
28. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, Newman J et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1999; 42: 299-305.
29. Freundlich B, Jimenez SA, Steen VD, Medsger Jr TA, Szkolnicki M, Jaffe HS. Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial. Arthritis Rheum 1992; 35: 1134-1142.
30. Enomoto DN, Mekkes JR, Bossuyt PM, Yong SL, Out TA, Hoekzema R et al. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis). J Am Acad Dermatol 1999; 41 915-922.
31. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-844.
32. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994; 37: 729-735.
33. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998; 25: 1325-1329.
34. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 1999; 18 455-461.
35. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-954.
36. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
37. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-736.
38. Griffiths B, Miles S, Hilary M, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-2378.
39. Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619.
40. Van Laar JM, Farge D, Tyndall A. Autologous stem cell transplantation international scleroderma (ASTIS) trial: Hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64 1515.